Share This Article:

The Role of CK20, p53 and p63 in Differentiation of Some Urothelial Lesions of Urinary Bladder, Immunohistochemical Study

Abstract Full-Text HTML XML Download Download as PDF (Size:3518KB) PP. 181-193
DOI: 10.4236/ojpathology.2014.44024    3,421 Downloads   4,614 Views   Citations

ABSTRACT

Background: Differentiation of urothelial hyperplasia, dysplasia and carcinoma in situ (CIS) may pose diagnostic difficulties. We aim to evaluate the role of CK20, p53 and p63 in differentiation of such lesions. Methods: we evaluate these markers in 213 cases of bladder lesions (14 hyperplasia, 7 dysplasia, 5 CIS, 25 noninvasive and 162 invasive urothelial carcinoma) in a retrospective study on sections from formalin-fixed, paraffin-embedded blocks. Cytoplasmic staining considered for CK20 and nuclear staining for p53 and p63. Results: CK20 was expressed in 14 out of 14 hyperplasia (4 strong, 7 moderate, 3 weak), in 7 out of 7 dysplasia (4 strong , 3 moderate), in 5 out of 5 CIS, in 19 out of 25 noninvasive carcinoma; strong in 11 (7 low grade, 4 high grade), moderate in 7 (5 low grade, 2 high grade), and weak in 1 case of low grade, in 136 out of 162 invasive carcinoma; strong in 46 (22 grade II, 24 grade III), moderate in 71 (2 grade I, 58 grade II, 11 grade III), and weak in 19 (2 grade I, 15 grade II, 2 grade III), no expression in 2 cases of grade IV. p53 was expressed in 7 out of 14 hyperplasia (weak in all cases), in 7 out of 7 dysplasia (5 strong, 2 moderate), in 5 out of 5 CIS (strong in all cases), in 20 out of 25 noninvasive carcinoma (8 strong, 9 moderate, 3 weak), in 135 out of 162 invasive carcinoma (34 strong, 73 moderate, 28 weak). p63 was expressed in 14 out of 14 hyperplasia, in 7 out of 7 dysplasia, in 4 out of 5 CIS, in 25 out of 25 noninvasive carcinoma, and in 134 out of 162 invasive carcinoma (28 strong, 63 moderate, 43 weak). CK20 was insignificant in noninvasive and significant in invasive carcinoma, while p53 and p63 were significant in noninvasive and invasive carcinoma. Conclusion: CK20, p53 and p63 are useful in differentiation of different bladder lesions.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Raheem, S. , Saied, A. , Shaer, R. , Mustafa, O. and Ali, A. (2014) The Role of CK20, p53 and p63 in Differentiation of Some Urothelial Lesions of Urinary Bladder, Immunohistochemical Study. Open Journal of Pathology, 4, 181-193. doi: 10.4236/ojpathology.2014.44024.

References

[1] Eble, J.N., Sauter, G., Epstein, J.I. and Sesterhenn, I.A. (2004) World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs. IARC Press, Lyon.
[2] Sangeeta, D., Lim, S.D., Jimenez, R.E., Chun, T., Keane, T.E., McKenney, J.K., Pompa, A.Z., Cohen, C., Young, R.H. and Amin, M.B. (2000) Relationship of Cytokeratin 20 and CD44 Protein Expression with WHO/ISUP Grade in pTa and pT1 Papillary Urothelial Neoplasia. Modern Pathology, 13, 1315-1323. http://dx.doi.org/10.1038/modpathol.3880241
[3] Sentürk, N., Aybek, Z. and Düzcan, E (2010) Ki-67, p53, Bcl-2 and Bax Expression in Urothelial Carcinomas of Urinary Bladder. Turkish Journal of Pathology, 26, 025-030.
[4] Pasin, E., Josephson, D.Y., Mitra, A.P., Cote, R.J. and Stein, J.P. (2008) Superficial Bladder Cancer: An Update on Etiology, Molecular Development, Classification, and Natural History. Reviews in Urology, 10, 1.
[5] Ramos, D., Navarro, S., Villamón, R., Gil-Salom, M. and Llombart-Bosch, A. (2003) Cytokeratin Expression Patterns in Low-Grade Papillary Urothelial Neoplasms of the Urinary Bladder. Cancer, 97, 1876-1883. http://dx.doi.org/10.1002/cncr.11265
[6] Cina, S.J., Epstein, J.I., Endrizzi, J.M., Harmon, W.J., Seay, T.M. and Schoenberg, M.P. (2001) Correlation of Cystoscopic Impression with Histologic Diagnosis of Biopsy Specimens of the Bladder. Human Pathology, 32, 630-637. http://dx.doi.org/10.1053/hupa.2001.24999
[7] Di Como, C.J., Urist, M.J., Babayan, I., Drobnjak, M., Hedvat, C.V., Teruya-Feldstein, J., Pohar, K., Hoos, A. and Cordon-Cardo, C. (2002) p63 Expression Profiles in Human Normal and Tumor Tissues. Clinical Cancer Research, 8, 494-501.
[8] Mallofré, C., Castillo, M., Morente, V. and Solé, M. (2003) Immunohistochemical Expression of CK20, p53, and Ki-67 as Objective Markers of Urothelial Dysplasia. Modern Pathology, 16, 187-191.
http://dx.doi.org/10.1097/01.MP.0000056628.38714.5D
[9] Stepan, A., Margaritescu, C.L., Simionescu, C. and Ciurea, R. (2009) E-cadherin and p63 Immunoexpression in Dysplastic Lesions and Urothelial Carcinomas of the Bladder. Romanian Journal of Morphology and Embryology, 50, 461-465.
[10] Yildiz, I.Z., Recavarren, R., Armah, H.B., Bastacky, S., Dhir, R. and Parwani, A.V. (2009) Utility of a Dual Immunostain Cocktail Comprising of p53 and CK20 to Aid in the Diagnosis of Non-Neoplastic and Neoplastic Bladder Biopsies. Diagnostic Pathology, 4, 35. http://dx.doi.org/10.1186/1746-1596-4-35
[11] Kaufmann, O., Fietze, E., Mengs, J. and Dietel, M. (2001) Value of p63 and Cytokeratin 5/6 as Immunohistochemical Markers for the Differential Diagnosis of Poorly Differentiated and Undifferentiated Carcinomas. American Journal of Clinical Pathology, 116, 823-830.
http://dx.doi.org/10.1309/21TW-2NDG-JRK4-PFJX
[12] Stigler, S. (2008) Fisher and the 5% Level. Chance, 21, 12. http://dx.doi.org/10.1007/s00144-008-0033-3
[13] Dallal, G.E. (2012) The Little Handbook of Statistical Practice. Tufts University Press, Boston.
[14] Southgate, J., Harnden, P. and Trejdosiewicz, L.K. (1999) Cytokeratin Expression Patterns in Normal and Malignant Urothelium: A Review of the Biological and Diagnostic Implications. Histology and Histopathology, 14, 657-664.
[15] Castillo-Martin, M., Domingo-Domenech, J., Karni-Schmidt, O., Matos, T. and Cordon-Cardo, C. (2010) Molecular Pathways of Urothelial Development and Bladder Tumorigenesis. Urologic Oncology, 28, 401-408. http://dx.doi.org/10.1016/j.urolonc.2009.04.019
[16] Harnden, P., Eardley, I., Joyce, A.D. and Southgate, J. (1996) Cytokeratin 20 as an Objective Marker of Urothelial Dysplasia. British Journal of Urology, 78, 870-875. http://dx.doi.org/10.1046/j.1464-410X.1996.23511.x
[17] McKenney, J.K., Gomez, J.A., Desai, S., Lee, M.W. and Amin, M.B. (2001) Morphologic Expressions of Urothelial Carcinoma in Situ: A Detailed Evaluation of Its Histologic Patterns with Emphasis on Carcinoma in Situ with Microinvasion. The American Journal of Surgical Pathology, 25, 356-362. http://dx.doi.org/10.1097/00000478-200103000-00010
[18] Yin, H., He, Q., Li, T. and Leong, A.S. (2006) Cytokeratin 20 and Ki-67 to Distinguish Carcinoma in Situ from Flat Non-Neoplastic Urothelium. Applied Immunohistochemistry Molecular Morphology, 14, 260-265. http://dx.doi.org/10.1097/00129039-200609000-00002
[19] Nese, N., Gupta, R., Bui, M.H. and Amin, M.B. (2009) Carcinoma in Situ of the Urinary Bladder: Review of Clinicopathologic Characteristics with an Emphasis on Aspects Related to Molecular Diagnostic Techniques and Prognosis. Journal of the National Comprehensive Cancer Network, 7, 48-57.
[20] Moll, R., Lowe, A., Laufer, J. and Franke, W. (1992) Cytokeratin 20 in Human Carcinomas. A New Histodiagnostic Marker Detected by Monoclonal Antibodies. American Journal of Pathology, 140, 427-447.
[21] Miettinen, M. (1995) Keratin 20: Immunohistochemical Marker for Gastrointestinal, Urothelial and Merkel Cell Carcinomas. Modern Pathology, 8, 384-388.
[22] Wang, N.P., Zee, S., Zarbo, R.J., Bacchi, C.E. and Gown, A.M. (1995) Coordinate Expression of Cytokeratins 7 and 20 Defines Unique Subsets of Carcinomas. Applied Immunohistochemistry, 113, 383-388.
[23] Kalantari, M. and Ahmadnia, H. (2007) p53 Overexpression in Bladder Urothelial Neoplasms New Aspect of World Health Organization/International Society of Urological Pathology Classification. Urology Journal, 4, 111-115.
[24] Soukup, V., Babjuk, M., Dusková, J., Pesl, M., Szakácsova, M., Zámefnik, L. and Dvorácek, J. (2007) The p53 Positivity in Non-Tumor Mucosa in Patients with Superficial Urinary Bladder Cancer. Casopis Lékaru Ceskych, 146, 63-67.
[25] Nakopoulou, L., Vourlakou, C., Zervas, A., Tzonou, A., Gakiopoulou, H. and Dimopoulos, M.A. (1998) The Prevalence of Bcl-2, p53 and Ki-67 Immunoreactivity in Transitional Cell Bladder Carcinomas and Their Clinicopathologic Correlates. Human Pathology, 29, 146-154. http://dx.doi.org/10.1016/S0046-8177(98)90225-8
[26] Thomas, D.J., Robinson, M.C., Charlton, R., Wilkinson, S., Shenton, B.K. and Neal, D.E. (1994) p53 Expression, Ploidy and Progression in pT1 Transitional Cell Carcinoma of the Bladder. British Journal of Urology, 73, 533-537. http://dx.doi.org/10.1111/j.1464-410X.1994.tb07639.x
[27] Burkhard, F.C., Markwalder, R., Thalmann, G.N. and Studer, U.E. (1997) Immunohistochemical Determination of p53 over Expression: An Easy and Readily Available Method to Identify Progression in Superficial Bladder Cancer. Urological Research, 25, S31-S35.
http://dx.doi.org/10.1007/BF00942045
[28] Grossman, H.B., Liebert, M., Antelo, M., Dinney, C.P., Hu, S., Palmer, J.L. and Benedict, W.F. (1998) p53 and RB Expression Predict Progression in T1 Bladder Cancer. Clinical Cancer Research, 4, 829-834.
[29] Uchida, T., Minei, S., Gao, J.P., Wang, C., Satoh, T. and Baba, S. (2002) Clinical Significance of p53, MDM2 and Bcl-2 Expression in Transitional Cell Carcinoma of the Bladder. Oncology Reports, 9, 253-259.
[30] Babjuk, M., Soukup, V., Mares, J., Duskova, J., Solace, Z., Trove, M., Pecan, L., Divorce, J., Hans, T., Novara, R., Novak, J. and Povysil, C. (2003) The Expression of PAX5, p53 Immunohistochemistry and p53 Mutation Analysis in Superficial Bladder Carcinoma Tissue. Correlation with Pathological Findings and Clinical Outcome. International Urology and Nephrology, 34, 495-501.
http://dx.doi.org/10.1023/A:1025652203472
[31] Venyo, A., Greenwood, H. and Maloney, D. (2010) The Expression of p53 in Human Urothelial Carcinoma. Webmed Central Urology, 1, 1-12.
[32] Yang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M.D., Dotsch, V., Andrews, N.C., Caput, D. and McKeon, F. (1998) p63, a p53 Homolog at 3q27-29, Encodes Multiple Products with Transactivation, Death-Inducing and Dominant-Negative Activities. Molecular Cell, 2, 305-316.
http://dx.doi.org/10.1016/S1097-2765(00)80275-0
[33] Koga, F., Kawakami, S., Kumagai, J., Takizawa, T., Ando, N., Arai1, G., Kageyama, Y. and Kihara, K. (2003) Impaired ΔNp63 Expression Associates with Reduced β-Catenin and Aggressive Phenotypes of Urothelial Neoplasms. British Journal of Cancer, 88, 740-747.
http://dx.doi.org/10.1038/sj.bjc.6600764
[34] Karni-Schmidt, O., Castillo-Martin, M., HuaiShen, T., Gladoun, N., Domingo-Domenech, J., Sanchez-Carbayo, M., Li, Y., Lowe, S., Prives, C. and Cordon-Cardo, C. (2011) Distinct Expression Profiles of p63 Variants during Urothelial Development and Bladder Cancer Progression. The American Journal of Pathology, 178, 159-165. http://dx.doi.org/10.1016/j.ajpath.2010.11.061
[35] Pignon, J.C., Grisanzio, C., Geng, Y., Song, J., Shivdasani, R.A. and Signoretti, S. (2013) p63-Expressing Cells Are the Stem Cells of Developing Prostate, Bladder and Colorectal Epithelia. Proceedings of the National Academy of Sciences of the United States of America, 110, 8105-8110. http://dx.doi.org/10.1073/pnas.1221216110
[36] Urist, M.J., Di Como, C.J., Lu, M.L., Charytonowicz, E., Verbel, D., Crum, C.P., Ince, T.A., McKeon, F.D. and Cordon-Cardo, C. (2002) Loss of p63 Expression Is Associated with Tumor Progression in Bladder Cancer. The American Journal of Pathology, 161, 1199-1206.
http://dx.doi.org/10.1016/S0002-9440(10)64396-9
[37] Chuang, A.Y., DeMarzo, A.M., Veltri, R.W., Sharma, R.B., Bieberich, C.J. and Epstein, J.I. (2007) Immunohistochemical Differentiation of High-Grade Prostate Carcinoma from Urothelial Carcinoma. The American Journal of Surgical Pathology, 31, 1246-1255.
http://dx.doi.org/10.1097/PAS.0b013e31802f5d33
[38] Srinivasan, M. and Parwani, A.V. (2011) Diagnostic Utility of p63/P501S Double Sequential Immunohistochemical Staining in Differentiating Urothelial Carcinoma from Prostate Carcinoma. Diagnostic Pathology, 6, 67. http://dx.doi.org/10.1186/1746-1596-6-67

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.